Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

180.94 USD UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EDT, Oct 27, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 897
Open 180.94
Bid (Size) 180.91 (1)
Ask (Size) 181.99 (1)
Prev. Close 180.94
Today's Range 180.94 - 180.94
52wk Range 176.36 - 242.99
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Vertex and Mammoth Biosciences Announce Collaboration to Develop In Vivo Gene-Editing Therapies for Serious Diseases
Mammoth Biosciences advances CRISPR platform, partnering with Vertex Pharmaceuticals to develop in vivo gene-editing therapies for serious diseases. 
From Business Wire News Releases
Vertex to Announce Third-Quarter 2021 Financial Results on November 2
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third-quarter 2021 financial results on Tuesday, November 2, 2021 after the financial markets close. The company will host a... 
From Business Wire News Releases

Performance

YTD
-21.13%
-21.13%
1 Month
-1.35%
-1.35%
3 Month
-10.53%
-10.53%
6 Month
-15.24%
-15.24%
1 Year
-14.73%
-14.73%

More News

Read More
Jennifer Doudna Spinout Mammoth Inks $700M CRISPR Deal With Vertex
Tags General Gene Editing Briefs
From Benzinga
Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)
From Business Wire News Releases
Notable Friday Option Activity: OLN, VRTX, STGW
Tags Stocks
From Market News Video
How Big Is Vertex's News for Its Potential Diabetes Cure?
Tags Market News VRTX
From Motley Fool
Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes
From Business Wire News Releases
December 3rd Options Now Available For Vertex Pharmaceuticals (VRTX)
Tags Stocks
From Market News Video
3 Stocks Cathie Wood Is Buying That You Might Want to Consider Too
Tags ARKW ARKG TDOC
From Motley Fool
Biotech Buyouts That Would Be Great for Investors
Tags NTLA CRSP REGN
From Motley Fool
3 of the Best Stocks to Buy Now With $500
Tags MTTR CRSP HYMTF
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.